Journal
CHEST
Volume 160, Issue 4, Pages 1471-1480Publisher
ELSEVIER
DOI: 10.1016/j.chest.2021.06.016
Keywords
anticoagulation; COVID-19; immunothrombosis; pulmonary embolism; VTE
Categories
Ask authors/readers for more resources
COVID-19 is associated with a significantly increased risk of pulmonary thrombosis, possibly driven by a hypercoagulable state and vascular injury. Some patients with COVID-19 may have hypoxemia that is disproportionate to impairment in lung compliance. Diagnosing PE in patients with COVID-19 can be challenging, leading many hospitals to implement aggressive anticoagulation protocols.
COVID-19, the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The predilection for thrombosis in COVID-19 may be driven by at least two distinct, but interrelated, processes: a hypercoagulable state responsible for large-vessel thrombosis and thromboembolism and direct vascular and endothelial injury responsible for in situ microvascular thrombosis. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism (PE) and COVID-19 pneumonia share many signs and symptoms, diagnosing PE in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19 and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard VTE prophylaxis. In this review, the epidemiologic and pathophysiologic features, diagnosis, and treatment of COVID-19 pulmonary thrombosis and thromboembolism are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available